The peptides frequently being referenced in reclassification conversations include: AOD-9604 BPC-157 Emideltide (DSIP Delta Sleep-Inducing Peptide) Epitalon (Epithalamin) GHK-Cu (Copper Peptide) Kisspeptin-10 KPV MOTS-C Semax Selank TB-500 (Thymosin Beta-4 Fragment) Thymosin Alpha-1 Despite public discussion, these peptides remain categorized as Category 2 under current FDA policy and are not eligible for patient-specific 503A compounding
Retrieved January 11, 2011
Thus, the anti-inflammatory action of BPC-157 might contribute partly to reversing acute thresholds or motor function induced by local tissue injury of inflammatory cytokines [22]
In paragraphs (d)(1)(i)(A)( 3 )( ii ), (d)(1)(i)(A)( 4 )( ii ), (d)(1)(ii)(A)( 3 )( ii ), (d)(1)(ii)(A)( 4 )( ii ), (d)(1)(iii)(A)( 3 )( ii ), (d)(1)(iii)(A)( 4 )( ii ), (d)(1)(iv)(A)( 3 )( ii ), (d)(1)(iv)(A)( 4 )( ii ), (d)(1)(v)(A)( 3 )( ii ), and (d)(1)(v)(A)( 4 )( ii ), removing the phrase health equity adjusted quality performance score calculated according to 425.512(b) and adding in its place the phrase quality score calculated according to 425.512
